– Dr. Deniger joins from National Cancer Institute to lead Ziopharm’s non-viral T-cell program targeting neoantigens for personalized immunotherapy of solid tumors – BOSTON , July 03, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew
Phase 2 trial will enroll approximately 30 patients and evaluate both safety and efficacy BOSTON , June 27, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the initiation of a phase 2 clinical trial evaluating Controlled IL-12
– Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study – BOSTON , June 26, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of
Operations Management Leader for Immunex, Dendreon; Co-Founder and Chief Strategy Officer of Vineti BOSTON , June 17, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Heidi Hagen , an experienced and entrepreneurial biotechnology
– Positions Ziopharm to be first company to bring non-viral TCR-T into the clinic – – Company to host informational conference call June 12, 2019 at 8:30 am ET – BOSTON , June 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) announced that the
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients confirmed rapid and safe activation of immune system – –Controlled IL-12 can be combined with increasing doses of a PD-1 inhibitor and immune profiling data is encouraging – BOSTON , June 02, 2019 (GLOBE NEWSWIRE) --
– Scope of license includes library of T-cell receptors (TCRs) against neoantigens in hotspots including mutated KRAS, p53 and EGFR for use with Sleeping Beauty platform – – Ziopharm also obtains license to manufacturing technologies for Sleeping Beauty -modifed TCR-expressing T cells targeting
BOSTON , May 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that Laurence Cooper , M.D., Ph.D., CEO of Ziopharm, is scheduled to participate in a webcast session at the
- Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors to begin at NCI in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 – - Phase 2 trial of Controlled IL-12 in combination with Regeneron’s Libtayo ® for patients
BOSTON , May 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Wednesday, May 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended March 31 , 2019.
